Abstract

ARANA-LUNA, Luara L. et al. Mexican consensus in acute myeloid leukemia in Mexico. Gac. Méd. Méx [online]. 2022, vol.158, n.spe3, pp.M1-M51.  Epub May 16, 2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m21000597.

Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.

Keywords : Acute myeloid leukemia; Myeloid blasts; Cytogenetic risk.